{"id":"NCT00618098","sponsor":"Octapharma","briefTitle":"Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures","officialTitle":"A Randomized, Open-label, Efficacy and Safety Study of Octaplex and Fresh Frozen Plasma (FFP) in Patients Under Vitamin K Antagonist Therapy With the Need for Urgent Surgery or Invasive Procedures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2012-03","completion":"2012-08","firstPosted":"2008-02-18","resultsPosted":"2023-01-31","lastUpdate":"2023-01-31"},"enrollment":200,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Reversal of Anticoagulant Treatment"],"interventions":[{"type":"BIOLOGICAL","name":"Octaplex (human prothrombin complex concentrate)","otherNames":[]},{"type":"BIOLOGICAL","name":"Fresh frozen plasma","otherNames":["FFP"]}],"arms":[{"label":"Octaplex (human prothrombin complex concentrate)","type":"EXPERIMENTAL"},{"label":"Fresh frozen plasma","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine whether Octaplex (human prothrombin complex concentrate) can reverse the effects of anticoagulants when compared to the standard treatment of fresh frozen plasma (FFP).","primaryOutcome":{"measure":"INR Response","timeFrame":"15 minutes after the end of first infusion of OCTAPLEX or FFP","effectByArm":[{"arm":"Octaplex (Human Prothrombin Complex Concentrate)","deltaMin":74,"sd":null},{"arm":"Fresh Frozen Plasma","deltaMin":31,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":12},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":97},"commonTop":["Hypotension","Nausea","Hypokalaemia","Constipation","Diarrhea"]}}